EUCTR2018-002757-30-ES
Active, not recruiting
Phase 1
A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa - Efficacy and safety of different investigational drugs for the treatment of hidradenitis suppurativa
ovartis Farmacéutica, S.A.0 sites90 target enrollmentMarch 6, 2020
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Hidradenitis suppurativa
- Sponsor
- ovartis Farmacéutica, S.A.
- Enrollment
- 90
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Male or female, age 18\-65 years, at least 50 kg body weight with moderate to severe HS
- •\- Clinically diagnosed HS for at least 12 months prior to screening
- •\- For Cohort A (iscalimab): at least 5 inflammatory lesions, no more than 10 fistulae and at least two anatomical area involved with HS lesions
- •\- For Cohort B (LYS006\): at least 3 inflammatory lesions; no more than 10 fistulae and at least two anatomical areas involved with HS lesions
- •Other protocol\-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 89
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •\- Use of other investigational drugs at the time of screening, or within 30 days or 5 half lives
- •of randomization, whichever is longer; or longer if required by local regulations; or
- •longer if required by local regulations
- •\- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for the subsequent 14 weeks after the last study drug administration for Cohort A (iscalimab) and the subsequent 2 weeks after the last study drug administration for Cohort B (LYS006\).
- •\- Pregnant or nursing (lactating) women at screening or randomization
- •Other protocol\-defined exclusion criteria may apply
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A randomized, subject and investigator blinded, placebo-controlled, multicenter study in parallel groups to assess the efficacy and safety of LYS006 in patients with moderate to severe inflammatory acneAcne10040790NL-OMON50746ovartis8
Active, not recruiting
Phase 1
A study to assess if CMK389 is effective, safe and tolerable in patients with moderate to severe Atopic Dermatitis (AD)EUCTR2020-003406-31-ESovartis Farmacéutica, S.A.64
Active, not recruiting
Phase 1
A study to assess if CMK389 is effective, safe and tolerable in patients with moderate to severe Atopic Dermatitis (AD)Moderate to Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2020-003406-31-HUovartis Pharma AG64
Active, not recruiting
Phase 1
A safety and efficacy study to learn how well JM112 works in patients with moderate to severe inflammatory acne.Moderate to Severe Inflammatory AcneMedDRA version: 19.1Level: LLTClassification code 10000519Term: Acne vulgarisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2016-002492-95-DEovartis Pharma AG75
Active, not recruiting
Phase 1
A safety and efficacy study to learn how well JM112 works in patients with moderate to severe inflammatory acne.Moderate to Severe Inflammatory AcneMedDRA version: 19.1 Level: LLT Classification code 10000519 Term: Acne vulgaris System Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2016-002492-95-NLovartis Pharma AG52